Although several novel biomarkers in cerebrospinal fluid, including amyloid-b (Aβ42), total tau, and phosphorylated tau, have been recommended for the diagnosis of AD, reflecting favorable diagnostic accuracy (Olsson et al., 2016); they were limited to the large-scale clinical screening application due to the invasive collection process and high cost. Here, MAPT is linked to Alzheimer disease.